Loading
Viz.ai
Viz.ai's Viz.ai One platform analyzes medical images and ECGs to detect suspected conditions such as stroke, hemorrhage, aneurysm, cardiomyopathy and pulmonary disease. It then coordinates care teams around those findings. As of 2026 it is used by 2,000+ US hospitals and health systems and trusted by 14 life science companies, and it has 50+ FDA-cleared solutions. It sells software to health systems and runs pharma and life-science partnerships, including a multi-year agreement with Bristol Myers Squibb for HCM detection. It was founded in 2016. Third-party trackers put its total funding at about $252M–$292M, depending on the source. Its largest round was a $100M Series D in 2022 at a $1.2B valuation, and it took on $40M of debt financing in 2023.
Funding
Every round, secondary, debt facility or acquisition involving Viz.ai that Lounge tracks, newest first.
No rounds recorded yet.
Paid members see the full deals desk — every AI round and exit, filterable by type, sector and country, with investors and reported ARR, plus CSV exports. Developer membership is $9/mo.
See plans →Log inKey numbers
—
0
—
—